Patient Selection for Ductal Carcinoma In Situ Observation Trials: Are the Lesions Truly Low Risk?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30016145.
- Also identified by DOI 10.2214/AJR.17.19244.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this article is to report on a study conducted to determine whether the lesions in patients with what is deemed to be low-risk ductal carcinoma in situ (DCIS) selected for two large clinical trials are in fact low-risk lesions. A retrospective review was conducted to determine whether the eligibility criteria of the two trials are predictive that DCIS is low risk. More than 20% of lesions are upgraded to invasive carcinoma in patients with low-risk DCIS as defined in two large clinical trials. More accurate methods are needed to determine whether patients with a diagnosis of low-grade DCIS can be treated less aggressively.
Medical subject headings
- Breast Neoplasms
- Carcinoma, Intraductal, Noninfiltrating
- Patient Selection